Pharmaceuticals

Immunibio Initiates Study to Evaluate Combination of Anktiva and AdHER2DC Cancer Vaccine Against Endometrial Cancer

bexib
By bexib 0 Min Read

The study aims to investigate Anktiva as a potential basis for future immunotherapy treatments for endometrial cancer and other cancers.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Fedi Launches Community-Focused Bitcoin Operating System
Next Article Lumen Technologies shares continue AI surge on bright cash flow outlook Reuters – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Trading: Finastra’s third-quarter win, technology trading
Banking
Financial institutions leverage AI to prepare for credit boom
Banking
Will realignment shape the future of American politics?
Economy
Nobel Prize in Economics for “Inclusive” Free Markets
Economy